Bioequivalence Study of Felodipine ER Tablets 10 mg Under Fed Conditions
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The study was conducted as an open-label, balanced, randomized, two-treatment, two-period,
two-sequence, single-dose, crossover, bioequivalence study comparing felodipine extended
release tablets USP 10 mg (containing felodipine 10 mg) manufactured by OHM Laboratories
Inc., NJ, 08901 with PLENDIL® extended release tablets 10 mg (containing felodipine 10 mg)
manufactured by Merck & Co. Inc. Whitehouse Station, NJ 08889 USA for AstraZeneca LP
Wilmington, DE 19850 in healthy, adult, male, human subjects under fed condition.